top of page
an_banners.png

News

Discover more about Annogen and how we support the identification of regulatory DNA elements and non-coding genetic variants to help improve patient, plant, and animal health.

an_banner1920x300.jpg
sign.jpg

BLOG

Insights blog - April 2024 

Considerations for developing safe and effective gene therapies: promoters

To improve safety and effectiveness of gene therapies, manufacturers can adjust three principal components: the therapeutic gene, the viral vector (including viral capsid) and the promoter. In this blog, we share insights from both recent publications and customer insights on how the latter element, promoters, are the next frontier in fine tuning and improving ATMP effectiveness. 

sign.jpg

NEWS

News - April 2024

Annogen Announces Research Collaboration for the Development of Cell Specific Promoters for Undisclosed Cell Therapy Company

Annogen announced a research collaboration for the identification of immune cell specific promoters for the use in a new cell therapy program for an undisclosed company. The developed regulatory elements will aid in developing safe and effective autologous T-cell therapies.  

sign.jpg

UPDATES

Updates - December 2023

Annogen signs deal in which SuRE™ libraries are used for in-vivo capsid screening

Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases for many capsids in parallel.

sign.jpg

UPDATES

Updates - October 2023

Annogen introduces HEK293-INDX1™
- a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production

Annogen is excited to share our latest breakthrough in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline expression and high inducibility with added stimulus.
 

sign.jpg

NEWS

NEWS- March 2023 Annogen enters  Contract Manufacturing market:
AIM™ services and SuRE™ promoters

AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development. 

Now it is also available to the contract manufacturing market: manufacturing virus and recombinant protein

sign.jpg

Vacancy

Annogen (Amsterdam) is recruiting a
Bioinformatician

We are looking for someone who is enthusiastic about science and has a strong desire to contribute to cutting-edge research. As a Bioinformatician at our organization, you will be responsible for analysing complex biological data sets and developing and implementing computational methods for data analysis.

sign.jpg

NEWS

PRESS RELEASE - January 2023 Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.

Annogen started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments 

sign.jpg

NEWS  

PRESS RELEASE - January 2023 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

Annogen to develop multiple CNS-cell specific promoters for VectorY targets.

sign.jpg

NEWS  

PRESS RELEASE - December 2022 Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences

Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery.

sign.jpg

NEWS

NEWS - November 2022 Annogen introduces AIM™ service

Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its proprietary SuRE™ barcoding strategy and previously established protocols, Annogen has now scaled a gene-insertion and expression mapping strategy to unprecedented numbers.

sign.jpg

NEWS

PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.    

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Novel approach could aid selective breeding in cattle

Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical traits, such as productivity or disease tolerance, in livestock.

The study, involving Roslin researchers and their commercial partner Annogen, will focus on identifying sites in cattle DNA linked to important genes for livestock production and welfare.

annogen.png

NEWS

NEWS – Annogen Featured in C2W

Many diseases are determined by differences in as yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome.

Read this article by Marysa van den Berg on the C2W website.

sign.jpg

NEWS

PRESS RELEASE – Amsterdam, 30 November 2021 Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company. 

Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants.

sign.jpg

NEWS

Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression

Annogen and KeyGene the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.

Sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently, Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field.

Annogen_Victor2.jpg

CBO APPOINTED

February 1, 2020 - Annogen appoints Victor Schut as Chief Business Officer

After supporting sister company Gen-X as CBO in 2019 and following the recent execution of its exclusive deal with Dutch gene therapy company uniQure he will now focus on setting up the spin-off business around the SuRE technology outside the gene therapy field.

Follow our activities on LinkedIn

  • LinkedIn - White Circle
bottom of page